UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 2,900 shares, a growth of 2,800.0% from the January 15th total of 100 shares. Based on an average daily trading volume, of 77,100 shares, the short-interest ratio is presently 0.0 days.

UCB Stock Performance

Shares of OTCMKTS:UCBJY opened at $98.94 on Thursday. UCB has a 52 week low of $49.55 and a 52 week high of $100.66. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm has a 50 day moving average of $97.56 and a 200 day moving average of $93.51.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.